Jove
Visualize
Contact Us

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Ras Gene02:38

The Ras Gene

6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  2. Systematic Pan-cancer Analysis Identified Rassf1 As An Immunological And Prognostic Biomarker And Validated In Lung Cancer.
  1. Home
  2. Systematic Pan-cancer Analysis Identified Rassf1 As An Immunological And Prognostic Biomarker And Validated In Lung Cancer.

Related Experiment Video

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

414

Systematic pan-cancer analysis identified RASSF1 as an immunological and prognostic biomarker and validated in lung

Yibing Bai1,2, Yuanyong Wang3, Jiapei Qin1,2

  • 1Medical School of Chinese PLA, Beijing, China.

Heliyon
|July 18, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Ras association domain family member 1 (RASSF1) is significantly downregulated in most cancers and correlates with prognosis and tumor immunity. RASSF1 may serve as a prognostic marker for precise immunotherapy, especially in lung cancer.

Keywords:
ImmunityLung cancerPan-cancerPrognosisRASSF1

More Related Videos

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

471
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K

Related Experiment Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

414
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

471
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Ras association domain family member 1 (RASSF1) encodes the RASSF1A protein, a crucial scaffold protein in cellular signaling networks.
  • RASSF1A's role in cancer development and its potential as a therapeutic target are areas of active investigation.

Purpose of the Study:

  • To investigate the immunological and prognostic significance of RASSF1 expression across diverse human cancers.
  • To specifically focus on the role of RASSF1 in lung cancer.

Main Methods:

  • Differential gene expression analysis using TCGA, GTEx, and CCLE databases.
  • Prognostic evaluation via Cox regression and Kaplan-Meier analyses.
  • Correlation analysis (Spearman's test) and pathway enrichment (GO, KEGG).
  • Validation through immunohistochemistry and qRT-PCR for RASSF1 protein and mRNA levels.
  • Main Results:

    • RASSF1 expression was significantly lower in tumor tissues compared to normal tissues across most cancers.
    • RASSF1 expression correlated significantly with prognosis in over 12 cancer types, often indicating poor overall survival (OS).
    • RASSF1 expression showed significant associations with immune checkpoint genes, tumor microenvironment factors, and Th17 cell differentiation pathways, particularly in lung cancer. Moderate correlation with PD-L1 was observed.

    Conclusions:

    • RASSF1 exhibits differential expression in 29 human cancers and plays a critical role in tumor immunity.
    • RASSF1 holds potential as a prognostic biomarker for guiding precise immunotherapy strategies, notably in lung cancer.